Interest in cancer vaccines is being reignited by a greater understanding of tumor immunology and the potential of combining immunogens with new breakthrough immunotherapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
02 November 2016
In the version of this article initially published, on p.1024, middle column, the quote, “We have ipilimumab....” should have read, “We have tremelimumab....” The error has been corrected in the HTML and PDF versions of the article.
References
Schumacher, T.N. & Schreiber, R.D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).
Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641–645 (2014).
Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387–1390 (2015).
Bouchie, A. & DeFrancesco, L. Nature Biotechnology's academic spinouts of 2015. Nat. Biotechnol. 34, 484–492 (2016).
Le, D.T. et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 36, 382–389 (2013).
Lutz, E.R., Kinkead, H., Jaffee, E.M. & Zheng, L. Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. OncoImmunology 3, e962401 (2014).
Garde, D. Aduro slips after trial patient comes down with a dangerous infection. Fierce Biotech, 24 November http://www.fiercebiotech.com/r-d/aduro-slips-after-trial-patient-comes-down-a-dangerous-infection (2015).
Feuerstein, A. Advaxis cancer immunotherapy on hold due to patient death. The Street, 6 October https://www.thestreet.com/story/13314660/1/advaxis-cancer-immunotherapy-on-hold-due-to-patient-death.html (2015).
Jochems, C. et al. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol. Immunother. 63, 407–418 (2014).
Chen, D.S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).
Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
Gulley, J.L. et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin. Cancer Res. 11, 3353–3362 (2005).
Fong, L. et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J. Natl. Cancer Inst. 106, dju268 (2014).
Sheikh, N. et al. Clonotypic diversification of intratumoral T cells following Sipuleucel-T treatment in prostate cancer subjects. Cancer Res. 76, 3711–3718 (2016).
Cha, E. et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci. Transl. Med. 6, 238ra70 (2014).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Branca, M. Rekindling cancer vaccines. Nat Biotechnol 34, 1019–1024 (2016). https://doi.org/10.1038/nbt.3690
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3690